Lead Product(s): Monoclonal antibody-based therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 16, 2020
This additional investment allows AgilVax to continue generating compelling preclinical data with their monoclonal antibody-drug conjugates targeting SLC7A11 (xCT).